akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLCakusherstvo-74Research ArticleОRIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИHORMONE REPLACEMENT THERAPY AND PREVENTION OF THROMBOTIC COMPLICATIONSЗАМЕСТИТЕЛЬНАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ И ПРОФИЛАКТИКА ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙВоробьевА. В.Vorob'evA. V.ЗимовинаУ. В.ZimovinaU. V.Rudi_u@mail.ruКвиквинияИ. З.KvikviniyaI. Z.ГБОУ ВПО «Первый МГМУ имени И.М. Сеченова» Минздрава РФ, МоскваРоссияFirst Moscow State Medical Sechenov University of the Ministry of Health Russian FederationRussian Federation201407062016822733Copyright © Vorob'ev A.V., Zimovina U.V., Kvikviniya I.Z., 20162016Воробьев А.В., Зимовина У.В., Квиквиния И.З.Vorob'ev A.V., Zimovina U.V., Kvikviniya I.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/74

Pathogenesis of thrombotic complication caused by hormone replacement therapy and influence of HRT on risk of venous and arterial thrombosis are reviewed. Questionable points of prophylaxis of thrombotic complication of hormone replacement therapy are discussed.

В статье рассмотрен патогенез тромботических осложнений при применении заместительной гормональной терапии, влияние ЗГТ на риск венозных и артериальных тромбозов. Дается обсуждение возможностей профилактики тромботических осложнений при применении ЗГТ.

ЗАМЕСТИТЕЛЬНАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯТРОМБОФИЛИЯАРТЕРИАЛЬНЫЕ ТРОМБОЗЫПРОФИЛАКТИКА ТРОМБОТИЧЕСКИХ ОСЛОЖНЕНИЙhormone replacement therapythrombophiliaarterial thrombosisprophylaxis of thrombotic complicationReferencesГригорян О.Р., Андреева, Е.Н., Дедов И.И. Менопаузальный синдром у женщин с нарушениями углеводного обмена. Научно-практическое руководство (второе издание). М. 2011.Grigoryan O.R., Andreeva, E.N., Dedov I.I. Menopausal syndrome in women with disorders of carbohydrate metabolism. Scientific and practical guide (second edition) [Menopauzal’nyi sindrom u zhenshchin s narusheniyami uglevodnogo obmena. Nauchno-prakticheskoe rukovodstvo (vtoroe izdanie)]. Moscow. 2011.Макацария А.Д., Бицадзе О.В. Тромбофилические состояния в акушерской практике. М. 2001; 704 с.Makatsariya A.D., Bitsadze O.V. Thrombophilic state in obstetric practice [Trombofilicheskie sostoyaniya v akusherskoi praktike]. Moscow. 2001; 704 s.Макацария А.Д., Мищенко А.Л., Бицадзе В.О. Синдром диссеминированного внутрисосудистого свертывания крови в акушерской практике. М. 2002; 523 с.Makatsariya A.D., Mishchenko A.L., Bitsadze V.O. Disseminated intravascular coagulation in obstetric practice [Sindrom disseminirovannogo vnutrisosudistogo svertyvaniya krovi v akusherskoi praktike]. Moscow. 2002; 523 s.Макацария А.Д., Бицадзе О.В. Тромбофилии и противотромботическая терапия в акушерской практике. М. 2003; 904 с.Makatsariya A.D., Bitsadze O.V. Thrombophilia and antithrombotic therapy in obstetric practice [Trombofilii i protivotromboticheskaya terapiya v akusherskoi praktike]. M. 2003; 904 s.Овсянникова Т.В., Шешукова Н.А. Возможности заместительной гормональной терапии в зависимости от периода климактерия. Гинекология. 2007; 9 (2).Ovsyannikova T.V., Sheshukova N.A. Ginekologiya. 2007; 9 (2).Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therap. Lancet. 2002; 360 (9337): 942-944.Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therap. Lancet. 2002; 360 (9337): 942-944.Braunstein J.B., Kershner D.W., Bray P., Gerstenblith G. et al. Interaction of Hemostatic Genetics With Hormone Therapy: New Insights To Explain Arterial Thrombosis in Postmenopausal Women. Chest. 2002; 121 (3): 906-920.Braunstein J.B., Kershner D.W., Bray P., Gerstenblith G. et al. Interaction of Hemostatic Genetics With Hormone Therapy: New Insights To Explain Arterial Thrombosis in Postmenopausal Women. Chest. 2002; 121 (3): 906-920.Braunstein J.В., Kershner D.W, Gerstenblith G. et al. Interaction of Hemostatic Genetics With Hormone Therapy: New Insights To Explain Arterial Thrombosis in Postmenopausal Women. CHEST. 2002; 121: 906-20.Braunstein J.В., Kershner D.W, Gerstenblith G. et al. Interaction of Hemostatic Genetics With Hormone Therapy: New Insights To Explain Arterial Thrombosis in Postmenopausal Women. CHEST. 2002; 121: 906-20.Brenner B.R., Kosch A., Manco-Johnson M., Laposata M. Diagnostic Studies for Thrombophilia in Women on Hormonal Therapy and During Pregnancy, and in Children. Arch. Pathol. Lab. Med. 2002; 126: 1296-303.Brenner B.R., Kosch A., Manco-Johnson M., Laposata M. Diagnostic Studies for Thrombophilia in Women on Hormonal Therapy and During Pregnancy, and in Children. Arch. Pathol. Lab. Med. 2002; 126: 1296-303.Cano A., Van Baal W M. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas. 2001; 40: 17-38.Cano A., Van Baal W M. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas. 2001; 40: 17-38.Cushman M., Kuller L.H., Prentice R. et al. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. J.A.M.A. 2004; 292 (13): 1573-80.Cushman M., Kuller L.H., Prentice R. et al. Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. J.A.M.A. 2004; 292 (13): 1573-80.Cushman M. Effects of Hormone Replacement Therapy and Estrogen Receptor Modulators on Markers of Inflammation and Coagulation. Amer. J. Cardiol. 2002; 90: 7F-10F.Cushman M. Effects of Hormone Replacement Therapy and Estrogen Receptor Modulators on Markers of Inflammation and Coagulation. Amer. J. Cardiol. 2002; 90: 7F-10F.Girolami A., Simioni P., Tormene D. APC resistance, oral contraceptive therapy and deep vein thrombosis: settled and unsettled problems. Haematologica. 2000; 85 (3): 225-6.Girolami A., Simioni P., Tormene D. APC resistance, oral contraceptive therapy and deep vein thrombosis: settled and unsettled problems. Haematologica. 2000; 85 (3): 225-6.Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann. Intern. Med. 2001; 135 (1): 1-8.Grodstein F., Manson J.E., Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann. Intern. Med. 2001; 135 (1): 1-8.Goudev A., Georgiev D. В., Koycheva N. et al. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas. 2002; 43; 49-53.Goudev A., Georgiev D. В., Koycheva N. et al. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas. 2002; 43; 49-53.Heckbert S.N.L., Lemaitre R.N., Reiner A. et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. J.A.M.A. 2004; 292 (13): 1581-7.Heckbert S.N.L., Lemaitre R.N., Reiner A. et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. J.A.M.A. 2004; 292 (13): 1581-7.Herrington D.M., Klein K.P. Effects of Estrogen on Thrombosis and Inflammation. Rev. Cardiovasc. Med. 2002; 3 (1): 49-56.Herrington D.M., Klein K.P. Effects of Estrogen on Thrombosis and Inflammation. Rev. Cardiovasc. Med. 2002; 3 (1): 49-56.Herkert O., Kuhl H., Sandow J., Busse R., Schini-Kerth V.B. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001 Dec 4; 104 (23): 2826-31.Herkert O., Kuhl H., Sandow J., Busse R., Schini-Kerth V.B. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001 Dec 4; 104 (23): 2826-31.Hodis H.N., Mack W.J., Lobo R.A. et al. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2001; 135 (11): 939-53.Hodis H.N., Mack W.J., Lobo R.A. et al. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2001; 135 (11): 939-53.Hoibraaten E., Qvigstad E., Arnesen H. et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, doubleblind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb. Haemost. 2000; 84 (6): 961-967.Hoibraaten E., Qvigstad E., Arnesen H. et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, doubleblind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb. Haemost. 2000; 84 (6): 961-967.Khan M.A., Heagerty A.M., Kitchener H., McNamee R., Cherry' N.M., Hannaford P. Oestrogen and women's heart disease: ESPRIT-UK. QJM. 2000; 93 (10): 699-700.Khan M.A., Heagerty A.M., Kitchener H., McNamee R., Cherry' N.M., Hannaford P. Oestrogen and women's heart disease: ESPRIT-UK. QJM. 2000; 93 (10): 699-700.Koh К.К. Effects of estrogen on the vascular wall: vasomotor function and Inflammation. Cardiovasc. Res. 2002; 55: 714-26.Koh К.К. Effects of estrogen on the vascular wall: vasomotor function and Inflammation. Cardiovasc. Res. 2002; 55: 714-26.Lowe G., Woodward M., Vessey M. et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb. Haemost. 2000; 83 (4): 530-5.Lowe G., Woodward M., Vessey M. et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb. Haemost. 2000; 83 (4): 530-5.Lu H., Higashikata T, Inazu A. et al. Association of Estrogen Receptor-a Gene Polymorphisms With Coronary Artery Disease in Patients With Familial Hypercholesterolemia. Arterioscler. Thromb. Vase. Biol. 2002; 22: 821-7.Lu H., Higashikata T, Inazu A. et al. Association of Estrogen Receptor-a Gene Polymorphisms With Coronary Artery Disease in Patients With Familial Hypercholesterolemia. Arterioscler. Thromb. Vase. Biol. 2002; 22: 821-7.Luyer P., Khosla S., Owen W.G., V. Miller. M. Prospective Randomized Study of Effects of Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women. J. Clin. Endocrinol. Metab. 2001; 86: 3629-34.Luyer P., Khosla S., Owen W.G., V. Miller. M. Prospective Randomized Study of Effects of Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women. J. Clin. Endocrinol. Metab. 2001; 86: 3629-34.Manson J.E., Hsia J., Johnson K.C. et al. Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 2003; 349 (6): 523-34.Manson J.E., Hsia J., Johnson K.C. et al. Women’s Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 2003; 349 (6): 523-34.Nelson H.D. Assessing Benefits and Harms of Hormone Replacement Therapy: Clinical Applications. JAMA. 2002; 288 (7): 882-884.Nelson H.D. Assessing Benefits and Harms of Hormone Replacement Therapy: Clinical Applications. JAMA. 2002; 288 (7): 882-884.Psaty B.M., Smith N.L., Lemaitre R.N. et al. Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women. JAMA. 2001; 285 (7): 906-913.Psaty B.M., Smith N.L., Lemaitre R.N. et al. Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women. JAMA. 2001; 285 (7): 906-913.Raghvendra K., Jackson E.K. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Amer. J. Physiol. Renal. Physiol. 2001; 280: F365-88.Raghvendra K., Jackson E.K. Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Amer. J. Physiol. Renal. Physiol. 2001; 280: F365-88.Pare G., Krust A., Karas R. H., Dupont S., Aronovitz M., Chambon P., Mendelsohn M. E. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res. 2002; 90 (10): 1087-92.Pare G., Krust A., Karas R. H., Dupont S., Aronovitz M., Chambon P., Mendelsohn M. E. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res. 2002; 90 (10): 1087-92.Peeyananjarassri K., Baber R. Effects of lowdose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric. 2005; 8 (1): 13-23.Peeyananjarassri K., Baber R. Effects of lowdose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric. 2005; 8 (1): 13-23.Pradhan A.D., Manson J.A., Rossouw J.E. et al. Inflammatory biomarkers, hormone replacement therapy and incidence of coronary heart disease. J.A.M.A. 2002; 288: 980-7.Pradhan A.D., Manson J.A., Rossouw J.E. et al. Inflammatory biomarkers, hormone replacement therapy and incidence of coronary heart disease. J.A.M.A. 2002; 288: 980-7.Psaty B.M., Smith N.L., Lemaitre R.N. et al. Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women. JAMA. 2001; 285 (7): 906-913.Psaty B.M., Smith N.L., Lemaitre R.N. et al. Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women. JAMA. 2001; 285 (7): 906-913.Rosendaal F.R., Vlieg A.V.H., Tanis B.C, Helmelhorst F.M. Estrogens, Progesterons and thorombosis. J. Thromb. Haemost. 2003; 1: 1371-80.Rosendaal F.R., Vlieg A.V.H., Tanis B.C, Helmelhorst F.M. Estrogens, Progesterons and thorombosis. J. Thromb. Haemost. 2003; 1: 1371-80.Rosendaal F.R., Vessey M., Rumley A. et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br. J. Haematol. 2002; 166 (4): 851-854.Rosendaal F.R., Vessey M., Rumley A. et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br. J. Haematol. 2002; 166 (4): 851-854.Scarabin P.Y., Oger E., Plu-Bureau G. Estrogen and ThromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 9382 (362): 428-432.Scarabin P.Y., Oger E., Plu-Bureau G. Estrogen and ThromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 9382 (362): 428-432.Schuit S.C.E., Oei H.H., Witteman J.C.M. et al. Estrogen Receptor Gene Polymorphisms and Risk of Myocardial Infarction. JAMA. 2004; 291 (24): 2969-2977.Schuit S.C.E., Oei H.H., Witteman J.C.M. et al. Estrogen Receptor Gene Polymorphisms and Risk of Myocardial Infarction. JAMA. 2004; 291 (24): 2969-2977.Seelig M.S., Altura B.M., Altura В.Т. Benefits and Risks of Sex Hormone Replacement in Postmenopausal Women. J. Amer. Coll. Nutr. 2004; 23 (5): 482-96.Seelig M.S., Altura B.M., Altura В.Т. Benefits and Risks of Sex Hormone Replacement in Postmenopausal Women. J. Amer. Coll. Nutr. 2004; 23 (5): 482-96.Stork S., van der Schouw Y.T., Grobbee D.E. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab. 2004; 15 (2): 66-72.Stork S., van der Schouw Y.T., Grobbee D.E. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab. 2004; 15 (2): 66-72.Tempfer C.B., Riener E.K., Hefler L.A., Huber J.C., Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril. 2004; 82 (1): 132-137.Tempfer C.B., Riener E.K., Hefler L.A., Huber J.C., Muendlein A. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy. Fertil Steril. 2004; 82 (1): 132-137.The Women’s Health Initiative Hormone Trials: Implications for Menopausal and Posmenopausal Women. 5th International Symposium on Women’s Health and menopause. Florence, 2004.The Women’s Health Initiative Hormone Trials: Implications for Menopausal and Posmenopausal Women. 5th International Symposium on Women’s Health and menopause. Florence, 2004.

The authors declare that there are no conflicts of interest present.